ESR1 and breast cancer: PHA upregulated ER expansion (+) (%) of breast cancer cells (MCF7 and MDA-MB-231) in a dose-response manner (Figure 1B), alleviated by N-acetylcysteine (NAC) pretreatment (ROS inhibitor).